
    
      Study Objectives:

      The objectives of this two-part, primary immunization and booster dose, study are to continue
      to collect safety data on Rift Valley Fever (RVF) Vaccine, Inactivated (TSI-GSD 200); and, to
      continue to collect immunogenicity data on Rift Valley Fever (RVF) Vaccine, Inactivated
      (TSI-GSD 200) and analyze interim data to determine whether a 6-month dose is indicated; and,
      to provide potential protection for personnel at risk for occupational exposure to the RVF
      virus and collect data on incidence of occupational RVF infection (subclinical and clinical)
      in immunized personnel.
    
  